Bisoprolol vs nebivolol

DLCO, as percent of predicted, was 69 15, 76 16 in Carvedilol, Nebivolol and Bisoprolol, respectively (= p b 0.0001 vs. Bisoprolol and Nebivolol). DLCO was ~10% lower in Carvedilol compared to Bisoprolol and Nebivolol, due to a ~20% reduction of DM with a partial compensatory increase of VC (Fig. 1).

Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial. Int J Cardiol. 25

Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial List of references Publications that cite

DLCO, as percent of predicted, was 69 15, 76 16 in Carvedilol, Nebivolol and Bisoprolol, respectively (= p b 0.0001 vs. Bisoprolol and Nebivolol). DLCO was ~10% lower in Carvedilol compared to Bisoprolol and Nebivolol, due to a ~20% reduction of DM with a partial compensatory increase of VC (Fig. 1).

by S Paolillo 2024 Cited by 31with pulmonary disease (bisoprolol, metoprolol, nebivolol), diabetes (carvedilol and nebivolol), atrial fibrillation NEbivolol, vs.

Nebivolol vs. Placebo. 2128 21 months. Death or hospitalisation. 14 bisoprolol, carvedilol, celiprolol, labetalol, metoprolol, nebivolol and

by S Ray 2024 Cited by 2Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in NEbivolol, vs. BIsoprolol in moderate heart failure

Metoprolol; Esmolol; Bisoprolol; Betaxolol; Bevantolol; Nebivolol See The sympathetic vs. parasympathetic nervous system for details

CARNEBI (Multiparametric comparison of CARvedilol, vs. Nebivolol, vs. Bisoprolol in moderate heart failure) showed improvement in exercise performance (p 0.0001) with nebivolol and Bisoprolol . Individual trials of both Nebivolol and Bisoprolol have shown that they reduce cardiovascular events.